MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jaad.2023.12.070

Медицинская библиотека · Journal of the American Academy of Dermatology · 2024

Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation.

Chat Vipawee S, Ellebrecht Christoph T, Kingston Paige, Gondo George, Bell Stacie, Cordoro Kelly M, Desai Seemal R, Duffin Kristina C, Feldman Steven R, Garg Amit, Gelfand Joel M, Gladman Dafna, Green Lawrence J, Gudjonsson Johann, Han George, Hawkes Jason E, Kircik Leon, Koo John, Langley Richard, Lebwohl Mark, Michael Lewitt G, Liao Wilson, Martin George, Orbai Ana-Maria, Reddy Soumya M, Richardson Veronica, Ritchlin Christopher T, Schwartzman Sergio, Siegel Evan L, Van Voorhees Abby S, Wallace Elizabeth B, Weinberg Jeffrey M, Winthrop Kevin L, Yamauchi Paul, Armstrong April W

СтатьяConsensus StatementПеревод в очереди

Аннотация

BACKGROUND

For psoriatic patients who need to receive nonlive or live vaccines, evidence-based recommendations are needed regarding whether to pause or continue systemic therapies for psoriasis and/or psoriatic arthritis.

OBJECTIVE

To evaluate literature regarding vaccine efficacy and safety and to generate consensus-based recommendations for adults receiving systemic therapies for psoriasis and/or psoriatic arthritis receiving nonlive or live vaccines.

METHODS

Using a modified Delphi process, 22 consensus statements were developed by the National Psoriasis Foundation Medical Board and COVID-19 Task Force, and infectious disease experts.

RESULTS

Key recommendations include continuing most oral and biologic therapies without modification for patients receiving nonlive vaccines; consider interruption of methotrexate for nonlive vaccines. For patients receiving live vaccines, discontinue most oral and biologic medications before and after administration of live vaccine. Specific recommendations include discontinuing most biologic therapies, except for abatacept, for 2-3 half-lives before live vaccine administration and deferring next dose 2-4 weeks after live vaccination.

LIMITATIONS: Studies regarding infection rates after vaccination are lacking.

CONCLUSION

Interruption of antipsoriatic oral and biologic therapies is generally not necessary for patients receiving nonlive vaccines. Temporary interruption of oral and biologic therapies before and after administration of live vaccines is recommended in most cases.

Для цитирования: Chat Vipawee S, Ellebrecht Christoph T, Kingston Paige, Gondo George, Bell Stacie, Cordoro Kelly M, Desai Seemal R, Duffin Kristina C, Feldman Steven R, Garg Amit, Gelfand Joel M, Gladman Dafna, Green Lawrence J, Gudjonsson Johann, Han George, Hawkes Jason E, Kircik Leon, Koo John, Langley Richard, Lebwohl Mark, Michael Lewitt G, Liao Wilson, Martin George, Orbai Ana-Maria, Reddy Soumya M, Richardson Veronica, Ritchlin Christopher T, Schwartzman Sergio, Siegel Evan L, Van Voorhees Abby S, Wallace Elizabeth B, Weinberg Jeffrey M, Winthrop Kevin L, Yamauchi Paul, Armstrong April W. Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation.. Journal of the American Academy of Dermatology. 2024. DOI: 10.1016/j.jaad.2023.12.070.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.